| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Xiaohui Xu, Keeley Brookes, Chih-Ken Chen, Yu-Shu Huang, Yu-Yu Wu, Philip Asherso. Association study between the monoamine oxidase A gene and attention deficit hyperactivity disorder in Taiwanese samples. BMC psychiatry. vol 7. 2007-03-19. PMID:17328795. |
molecular genetic and pharmacological studies suggest the involvement of the dopaminergic, serotonergic and noradrenergic neurotransmitter systems in the pathogenesis of adhd. |
2007-03-19 |
2023-08-12 |
Not clear |
| Alexandra Philipsen, Magdolna Hornyak, Dieter Rieman. Sleep and sleep disorders in adults with attention deficit/hyperactivity disorder. Sleep medicine reviews. vol 10. issue 6. 2007-03-01. PMID:17084648. |
in particular, rls was suggested to be highly associated with adhd, indicating a probable common central nervous dopaminergic dysfunction. |
2007-03-01 |
2023-08-12 |
Not clear |
| Mohammad Reza Mohammadi, Shahin Akhondzade. Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches. Expert review of neurotherapeutics. vol 7. issue 2. 2007-02-27. PMID:17286552. |
several nonstimulant medications that affect noradrenergic and/or dopaminergic pathways have demonstrated efficacy in the treatment of adhd, although effect sizes are comparable with methylphenidate, fewer data have accumulated regarding the safety profile of nonstimulants in general. |
2007-02-27 |
2023-08-12 |
Not clear |
| Alexandra S Potter, Paul A Newhouse, David J Bucc. Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/hyperactivity disorder? Behavioural brain research. vol 175. issue 2. 2007-01-11. PMID:17081628. |
theories of the neurobiological basis of attention-deficit/hyperactivity disorder (adhd) have largely focused on dysregulation of central dopaminergic function. |
2007-01-11 |
2023-08-12 |
Not clear |
| Catharine A Winstanley, Dawn M Eagle, Trevor W Robbin. Behavioral models of impulsivity in relation to ADHD: translation between clinical and preclinical studies. Clinical psychology review. vol 26. issue 4. 2006-12-12. PMID:16504359. |
furthermore, the contributions made by preclinical studies using such methodology to improve our understanding of the neural and neurochemical basis of impulsivity and adhd are discussed, with particular reference to the involvement of both the serotonergic and dopaminergic systems, and frontostriatal circuitry. |
2006-12-12 |
2023-08-12 |
human |
| David J Heal, David M Pierc. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS drugs. vol 20. issue 9. 2006-11-28. PMID:16953648. |
for these drugs, their abilities not only to ameliorate the behavioural and cognitive dysfunctions in adhd, but also to induce the common adverse effects of reduced appetite, nausea/vomiting and stomach ache, are almost certainly due to their ability to potentiate noradrenergic and/or dopaminergic function in the central and peripheral nervous systems. |
2006-11-28 |
2023-08-12 |
Not clear |
| Pedro Cabra. Attention deficit disorders: are we barking up the wrong tree? European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. vol 10. issue 2. 2006-09-12. PMID:16617029. |
beside the well documented dopaminergic effects of stimulant medication used in add and adhd, a more important role must be assigned to noradrenaline (na). |
2006-09-12 |
2023-08-12 |
Not clear |
| Philip Hazel. Do adrenergically active drugs have a role in the first-line treatment of attention-deficit/hyperactivity disorder? Expert opinion on pharmacotherapy. vol 6. issue 12. 2006-06-01. PMID:16197353. |
in addition to a longer duration of treatment effect than the predominantly dopaminergic psychostimulant drugs, a theoretical advantage of the adrenergically active drugs is a lesser tendency to aggravate common comorbidities of adhd, such as anxiety, obsessionality, depression and tics. |
2006-06-01 |
2023-08-12 |
Not clear |
| Anita Thapar, Michael O'Donovan, Michael J Owe. The genetics of attention deficit hyperactivity disorder. Human molecular genetics. vol 14 Spec No. 2. 2006-05-23. PMID:16244326. |
in contrast, evidence from pharmacological, neuroimaging and animal studies has suggested the involvement of specific neurotransmitter systems, notably dopaminergic pathways, in adhd and these aetiological clues have inspired a fruitful application of the candidate gene association approach. |
2006-05-23 |
2023-08-12 |
Not clear |
| N Laurin, V L Misener, J Crosbie, A Ickowicz, T Pathare, W Roberts, M Malone, R Tannock, R Schachar, J L Kennedy, C L Bar. Association of the calcyon gene (DRD1IP) with attention deficit/hyperactivity disorder. Molecular psychiatry. vol 10. issue 12. 2006-03-01. PMID:16172615. |
the dopaminergic system has been hypothesized to be involved in the development of adhd. |
2006-03-01 |
2023-08-12 |
Not clear |
| Ziarih Hawi, Ricardo Segurado, Judith Conroy, Karen Sheehan, Naomi Lowe, Aiveen Kirley, Denis Shields, Michael Fitzgerald, Louise Gallagher, Michael Gil. Preferential transmission of paternal alleles at risk genes in attention-deficit/hyperactivity disorder. American journal of human genetics. vol 77. issue 6. 2006-01-30. PMID:16380908. |
pharmacological, neuroimaging, and animal-model findings suggest imbalances in monoaminergic (dopaminergic, serotonergic, and noradrenergic) neurotransmission in adhd. |
2006-01-30 |
2023-08-12 |
Not clear |
| Ziarih Hawi, Ricardo Segurado, Judith Conroy, Karen Sheehan, Naomi Lowe, Aiveen Kirley, Denis Shields, Michael Fitzgerald, Louise Gallagher, Michael Gil. Preferential transmission of paternal alleles at risk genes in attention-deficit/hyperactivity disorder. American journal of human genetics. vol 77. issue 6. 2006-01-30. PMID:16380908. |
we have examined monoaminergic candidate genes for possible genetic association with adhd in the irish population, focusing particularly on genes of the dopaminergic and serotonergic systems. |
2006-01-30 |
2023-08-12 |
Not clear |
| Rui D S Prediger, Fabrício A Pamplona, Daniel Fernandes, Reinaldo N Takahash. Caffeine improves spatial learning deficits in an animal model of attention deficit hyperactivity disorder (ADHD) -- the spontaneously hypertensive rat (SHR). The international journal of neuropsychopharmacology. vol 8. issue 4. 2006-01-05. PMID:15877934. |
converging evidence suggests a primary role of disturbance in the dopaminergic neurotransmission in adhd patients and in shr, and in addition, some studies have also demonstrated alterations in adenosinergic neurotransmission in shr. |
2006-01-05 |
2023-08-12 |
rat |
| George A Ricaurte, Annis O Mechan, Jie Yuan, George Hatzidimitriou, Tao Xie, Andrew H Mayne, Una D McCan. Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates. The Journal of pharmacology and experimental therapeutics. vol 315. issue 1. 2005-11-28. PMID:16014752. |
here we demonstrate that amphetamine treatment, similar to that used clinically for adult adhd, damages dopaminergic nerve endings in the striatum of adult nonhuman primates. |
2005-11-28 |
2023-08-12 |
Not clear |
| George A Ricaurte, Annis O Mechan, Jie Yuan, George Hatzidimitriou, Tao Xie, Andrew H Mayne, Una D McCan. Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates. The Journal of pharmacology and experimental therapeutics. vol 315. issue 1. 2005-11-28. PMID:16014752. |
furthermore, plasma concentrations of amphetamine associated with dopaminergic neurotoxicity in nonhuman primates are on the order of those reported in young patients receiving amphetamine for the management of adhd. |
2005-11-28 |
2023-08-12 |
Not clear |
| Joseph Biederma. Attention-deficit/hyperactivity disorder: a selective overview. Biological psychiatry. vol 57. issue 11. 2005-07-29. PMID:15949990. |
structural and functional imaging studies suggest that dysfunction in the fronto-subcortical pathways, as well as imbalances in the dopaminergic and noradrenergic systems, contribute to the pathophysiology of adhd. |
2005-07-29 |
2023-08-12 |
Not clear |
| Joseph Biederma. Attention-deficit/hyperactivity disorder: a selective overview. Biological psychiatry. vol 57. issue 11. 2005-07-29. PMID:15949990. |
medication with dopaminergic and noradrenergic activity seems to reduce adhd symptoms by blocking dopamine and norepinephrine reuptake. |
2005-07-29 |
2023-08-12 |
Not clear |
| Joseph Biederma. Attention-deficit/hyperactivity disorder: a selective overview. Biological psychiatry. vol 57. issue 11. 2005-07-29. PMID:15949990. |
such alterations in dopaminergic and noradrenergic function are apparently necessary for the clinical efficacy of pharmacologic treatments of adhd. |
2005-07-29 |
2023-08-12 |
Not clear |
| Bertha K Madras, Gregory M Miller, Alan J Fischma. The dopamine transporter and attention-deficit/hyperactivity disorder. Biological psychiatry. vol 57. issue 11. 2005-07-29. PMID:15950014. |
thus, adhd medications targeting dat or net might disperse dopamine widely and consign dopamine storage and release to regulation by noradrenergic, as well as dopaminergic neurons. |
2005-07-29 |
2023-08-12 |
human |
| Luis Augusto Rohde, Cláudia Szobot, Guilherme Polanczyk, Marcelo Schmitz, Silvia Martins, Silzá Tramontin. Attention-deficit/hyperactivity disorder in a diverse culture: do research and clinical findings support the notion of a cultural construct for the disorder? Biological psychiatry. vol 57. issue 11. 2005-07-29. PMID:15950018. |
the prevalence rates of adhd (5.8% using dsm-iv criteria, 1.5% using icd-10), the bi-dimensional factor construct extracted from factor analyses (inattention and hyperactivity/impulsivity), the pattern of adhd comorbidity in clinical samples, the family genetic data suggesting a 39% family transmission in clinical samples and the role of some potential candidate genes in dopaminergic and noradrenergic systems, as well as data on the efficacy of methylphenidate in the disorder are all very similar to findings from developed countries. |
2005-07-29 |
2023-08-12 |
Not clear |